Globe Newswire09.01.20
EDAP TMS SA, the global leader in robotic energy-based therapies, announced that veteran medical technology executive Marie Meynadier has been elected to its Board of Directors, following a vote by the company’s shareholders. Meynadier has more than 20 years of experience in medical technology operations and leadership and most recently served as CEO of EOS Imaging.
Marc Oczachowski, chairman and CEO of EDAP, commented, “Marie has broad experience as both senior executive and director in the medtech field, in particular in the capital equipment area, and we are very pleased that she has joined our board. We look forward to her insights and contributions as we refine our research and development programs and work to efficiently expand our HIFU technology into other high-value indications where improved patient outcomes are badly needed.”
Meynadier currently serves on the Boards of Directors of several medical technology companies in Europe and North America. From 1999 through 2019, she served at EOS Imaging as its CEO and led the company through a period of rapid worldwide sales growth, increasing at a compound annual growth rate of 32 percent from 2012 to 2017. Prior to EOS Imaging, Meynadier served as CEO at Biospace Lab, a preclinical imaging company she developed and turned to profitability. Meynadier received a degree in electrical engineering from Sup Télécom, Paris, and her Ph.D. in physics from Ecole Normale Supérieure Ulm, Paris.
Meynadier stated, “I have had and continue to have the privilege of working alongside teams that produce truly groundbreaking and life-saving technologies, and I would firmly place EDAP’s high-intensity focused ultrasound in that category. Together with the Company’s recently announced partnership with Exact Imaging, I believe EDAP’s end-to-end Focal One solution represents a significant advancement in the treatment and ablation of not only prostate tissue, but other soft tissue indications as well. I look forward to working with the EDAP team and my fellow board members to help the Company realize its vast potential.”
Marc Oczachowski, chairman and CEO of EDAP, commented, “Marie has broad experience as both senior executive and director in the medtech field, in particular in the capital equipment area, and we are very pleased that she has joined our board. We look forward to her insights and contributions as we refine our research and development programs and work to efficiently expand our HIFU technology into other high-value indications where improved patient outcomes are badly needed.”
Meynadier currently serves on the Boards of Directors of several medical technology companies in Europe and North America. From 1999 through 2019, she served at EOS Imaging as its CEO and led the company through a period of rapid worldwide sales growth, increasing at a compound annual growth rate of 32 percent from 2012 to 2017. Prior to EOS Imaging, Meynadier served as CEO at Biospace Lab, a preclinical imaging company she developed and turned to profitability. Meynadier received a degree in electrical engineering from Sup Télécom, Paris, and her Ph.D. in physics from Ecole Normale Supérieure Ulm, Paris.
Meynadier stated, “I have had and continue to have the privilege of working alongside teams that produce truly groundbreaking and life-saving technologies, and I would firmly place EDAP’s high-intensity focused ultrasound in that category. Together with the Company’s recently announced partnership with Exact Imaging, I believe EDAP’s end-to-end Focal One solution represents a significant advancement in the treatment and ablation of not only prostate tissue, but other soft tissue indications as well. I look forward to working with the EDAP team and my fellow board members to help the Company realize its vast potential.”
